Abbott is trading 4.2% up today at $108.87 after receiving FDA clearance for its SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults 45 and older.
- The new non-invasive test is viewed as a major product win in the diagnostics space, significantly lifting investor sentiment.
- Shares are also benefiting from a broader rally in healthcare stocks driven by strong sector earnings and increased institutional buying.